TrialSignal
Clinical trial intelligence report
Valproate (Valproic Acid) and Etoposide for Patients With Progressive, Relapsed or Refractory Neuronal Tumors and Brain Metastases
Source-linked diligence brief with registry provenance, taxonomy normalization and premium analytical context.
Generated
Jul 28, 2026
Report code
NCT00513162-Jul 28, 2026
NCT ID
NCT00513162
Status
COMPLETED
Phase
PHASE1
Sponsor
M.D. Anderson Cancer Center
Executive brief
Investment-Ready Snapshot
Valproate (Valproic Acid) and Etoposide for Patients With Progressive, Relapsed or Refractory Neuronal Tumors and Brain Metastases is a PHASE1 clinical asset sponsored by M.D. Anderson Cancer Center in Neuroectodermal Tumor, Brain Metastases, Advanced Cancer. SEO and diligence focus: Valproate, Etoposide, endpoint relevance, enrollment feasibility, competitive positioning, readout timing and IP durability.
Source & freshness
Provenance
https://clinicaltrials.gov/study/NCT00513162
Indication
Neuroectodermal Tumor
Modality
small molecule
Target
Valproate, Etoposide
Intervention
Valproate, Etoposide
Source record
Protocol Description
Detailed source ingestion pending.
Source record
Outcome Measures
Detailed source ingestion pending.
Source record
Eligibility
Detailed source ingestion pending.
AI analysis
Known Results And Readout Context
Detailed source ingestion pending.
IP intelligence
Patent And IP Landscape
Detailed source ingestion pending.
Source record
Contacts
Detailed source ingestion pending.